NCT00984282 - Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | Biotech Hunter

Enrollment

417

Participants

Timeline

Start Date

October 15, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 30, 2017

Conditions

Thyroid Neoplasms

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).

DRUG

Placebo

Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).

Trial Locations (81)

1000

Bruxelles - Brussel

1090

Vienna

1527

Sofia

5000

Odense C

10029

New York

11211

Riyadh

13273

Marseille

14076

Caen

16132

Genoa

19104

Philadelphia

20122

Milan

20133

Milan

20162

Milan

28222

Majadahonda

30322

Atlanta

33076

Bordeaux

45122

Essen

48109

Ann Arbor

49933

Angers

50924

Cologne

53100

Siena

56124

Pisa

59037

Lille

63110

St Louis

69373

Lyon

75651

Paris

77030

Houston

80131

Napoli

81377

München

87106

Albuquerque

90048

Los Angeles

91054

Erlangen

94805

Villejuif

95029

Catania

97080

Würzburg

100021

Beijing

100730

Beijing

200030

Shanghai

200127

Shanghai

249036

Obninsk

300060

Tianjin

310022

Hangzhou

510060

Guangzhou

610041

Chengdu

94305-5820

Stanford

06520

New Haven

02118

Boston

15213-1863

Pittsburgh

98109-1023

Seattle

04103

Leipzig

06126

Perugia

464-8681

Nagoya

466-8560

Nagoya

277-8577

Kashiwa

135-8550

Koto-ku

9713 GZ

Groningen

2333 ZA

Leiden

44-101

Gliwice

60-355

Poznan

02-781

Warsaw

04-141

Warsaw

138-736

Asan Medical Center, Seoul

301-721

Daejeon

110-744

Seoul

120-752

Seoul

135-710

Seoul

137-701

Seoul

08035

Barcelona

413 45

Gothenburg

581 85

Linköping

221 85

Lund

171 76

Stockholm

AB25 2ZN

Aberdeen

CF14 2TL

Cardiff

G12 0YN

Glasgow

LS9 7TF

Leeds

SE1 9RT

London

SM2 5PT

London

Sutton

M20 4BX

Manchester

NE7 7DN

Newcastle upon Tyne